SEATTLE--(BUSINESS WIRE)--BEAT BioTherapeutics Corporation (BEATBio) announced today that co-founder and Scientific Advisory Board member, Dr. Michael Regnier, will present at the upcoming American Society for Gene and Cell Therapy annual meeting on May 13, 2015, in New Orleans, LA. Dr. Regnier will speak about “Gene Therapy Mediated Increase in dATP Improves Cardiac Performance in Models of Systolic Heart Failure.” He will summarize his recent work with BEATBio’s BB-R12 gene therapy being developed for the treatment of human heart failure, and he will also present data from new studies in mouse models of familial dilated cardiomyopathy, another cause of human heart failure.
Help employers find you! Check out all the jobs and post your resume.
